Every Form 4 that Beyond Air, Inc. (XAIR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. Chief Executive Officer Robert Scott Goodman purchased 34,722 shares of common stock on July 29, 2026 at $5.76 per share, bringing his direct common stock holdings to 34,822 shares. He also acquired 34,722 Series A Warrants and 34,722 Series B Warrants, each exercisable for common stock at $5.51 per share. The warrants are exercisable immediately; the Series A Warrants expire on the earlier of one year after issuance or 45 days following FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance.
Beyond Air, Inc. Chief Financial Officer Daniel J. Moorhead reported purchases on 2026-07-29 of 4,340 shares of common stock at $5.76 per share, along with 4,340 Series A Warrants and 4,340 Series B Warrants, each exercisable for common stock at $5.51 per share. The Series A Warrants are exercisable immediately and expire on the earlier of one year from issuance or 45 days after FDA approval of the company’s pending premarket approval supplement for LungFit PH II, while the Series B Warrants expire five years after issuance. Following these transactions, Moorhead holds 4,340 common shares, 4,340 Series A Warrants and 4,340 Series B Warrants directly.
Beyond Air, Inc. granted its Chief Financial Officer, Daniel J. Moorhead, a new stock option award. On January 5, 2026, he received an inducement grant of options to buy 70,000 shares of common stock at an exercise price of $0.79 per share, matching the closing price on January 2, 2026. The options expire on January 4, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 5, 2026, and the remaining 75% vest in three equal annual installments after that, as long as he remains employed. Any portion that is unexercisable when his employment ends will not become exercisable later. After this grant, he beneficially owns 70,000 stock options directly.
Beyond Air, Inc. (XAIR) reported an insider equity change for a director on Form 4. On November 4, 2025, the Board approved an option repricing effective that same day, reducing the exercise price of multiple stock option grants to $1.95 per share, which matches the closing price of Beyond Air’s common stock on November 3, 2025.
The filing shows that previously granted stock options with higher exercise prices, including options priced at $10.80 and $5.892 per share, were adjusted to the new $1.95 level. All other terms of the options, such as the number of underlying shares and expiration dates, remain unchanged.
The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan. They continue to vest according to the original vesting schedules set out in the award agreements, contingent on the reporting person’s continued service with Beyond Air on the applicable vesting dates.
Beyond Air, Inc. (XAIR) filed a Form 4 reporting that its Chief Operating Officer had existing stock options repriced. On November 4, 2025, the Board of Directors approved an option repricing, effective the same day, reducing the exercise price of several option grants to $1.95 per share, which was the closing price of Beyond Air’s common stock on November 3, 2025. All other terms of the options, including the number of shares and expiration details, remain unchanged.
The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan. They become exercisable based on the vesting schedule in the original award agreements, which continue to require the reporting person’s ongoing service with the company on each vesting date.
Beyond Air (XAIR) reported an insider equity update: a director’s outstanding stock options were repriced by the board to an exercise price of $1.95 per share, effective November 4, 2025. The new price matches the closing price on November 3, 2025, and all other terms, including vesting, remain unchanged under the company’s Amended and Restated 2013 Equity Incentive Plan.
The filing lists multiple option grants adjusted from prior exercise prices of $10.80 and $5.892 to $1.95, with representative tranches of 10,000, 4,500, 2,000, 1,500, and 1,250 options now reflecting the revised strike price.
Beyond Air, Inc. (XAIR) director reported warrant transactions on Form 4. In connection with a $2,000,000 loan to the company, the reporting person acquired warrants to purchase up to 512,821 shares at $1.95. Separately, an outstanding warrant for 494,332 shares at $7.586 was cancelled and a replacement warrant for 494,332 shares at $1.95 was issued. The warrants are exercisable on or after issuance and expire five years from their respective issuance dates.
Beyond Air, Inc. (XAIR) disclosed a director Form 4 reflecting a board-approved option repricing. On November 4, 2025, the board reduced the exercise price of certain outstanding stock options to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025.
The Form 4 shows multiple option awards previously carrying exercise prices of $10.80 and $5.892, each adjusted to $1.95. The company states that all other terms of the options remain unchanged. These options were granted under the Amended and Restated 2013 Equity Incentive Plan and continue to follow their existing vesting schedules, subject to the director’s continued service.
Beyond Air (XAIR) reported insider activity on a Form 4 detailing an option repricing for its Chief Financial Officer effective November 4, 2025. The exercise price of certain stock options was reduced to $1.95 per share, the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing shows cancellations of options previously priced at $10.80 and $5.892 and grants at $1.95 in equivalent amounts, including 15,000, 6,000, 3,750, 1,000, and 17,500 options. Following the reported transactions, the CFO beneficially owns 47,500 derivative securities directly. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and will vest per the original award agreements, subject to continued service.
Beyond Air, Inc. (XAIR) reported a Form 4 showing an option repricing approved by its Board on November 4, 2025. The exercise price of certain director stock options was reduced to $1.95 per share, which was the closing price of the company’s common stock on November 3, 2025. All other terms of the options remain unchanged.
The filing reflects paired transactions where options previously carrying a $10.80 exercise price were disposed and corresponding options with a $1.95 exercise price were acquired. Table entries include examples of 187 option units repriced per line item. The options were granted under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest as previously reported, subject to the reporting person’s continued service.
Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.
The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.
Beyond Air (XAIR) director reported an option repricing. On November 4, 2025, multiple stock option grants were repriced to an exercise price of $1.95 per share, effective the same day. The filing shows cancellations of prior options at higher strike prices (including $10.80 and $5.892) and corresponding grants at $1.95 for the same share amounts.
The company states that all other terms of the options remain unchanged. These awards were issued under the Amended and Restated 2013 Equity Incentive Plan and remain subject to the existing vesting schedules and the reporting person’s continued service.
Beyond Air (XAIR) disclosed an insider derivative change by CEO and Chairman Steven A. Lisi. On 11/03/2025, he canceled 164,778 warrants with a $7.586 exercise price and received a replacement warrant for 164,778 shares at $1.95. The warrant was originally issued on September 27, 2024, became exercisable on November 22, 2024, and will expire five years from November 22, 2024. Following these transactions, he directly holds 164,778 warrants.